- Home
- WF vs RPRX Comparison
WF vs RPRX Comparison
Compare WF & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WF
- RPRX
- Stock Information
- Founded
- WF 1899
- RPRX 1996
- Country
- WF South Korea
- RPRX United States
- Employees
- WF N/A
- RPRX N/A
- Industry
- WF Commercial Banks
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- WF Finance
- RPRX Health Care
- Exchange
- WF Nasdaq
- RPRX Nasdaq
- Market Cap
- WF 13.6B
- RPRX 13.9B
- IPO Year
- WF N/A
- RPRX 2020
- Fundamental
- Price
- WF $54.95
- RPRX $37.74
- Analyst Decision
- WF
- RPRX Strong Buy
- Analyst Count
- WF 0
- RPRX 4
- Target Price
- WF N/A
- RPRX $46.75
- AVG Volume (30 Days)
- WF 90.3K
- RPRX 2.5M
- Earning Date
- WF 08-19-2025
- RPRX 08-06-2025
- Dividend Yield
- WF 3.85%
- RPRX 2.38%
- EPS Growth
- WF 7.66
- RPRX 43.84
- EPS
- WF 2.76
- RPRX 2.16
- Revenue
- WF $7,783,057,365.00
- RPRX $2,304,578,000.00
- Revenue This Year
- WF N/A
- RPRX $28.60
- Revenue Next Year
- WF $2.38
- RPRX $8.07
- P/E Ratio
- WF $6.58
- RPRX $17.14
- Revenue Growth
- WF 1.22
- RPRX 2.99
- 52 Week Low
- WF $29.44
- RPRX $24.05
- 52 Week High
- WF $57.97
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- WF 56.58
- RPRX 57.95
- Support Level
- WF $50.37
- RPRX $36.27
- Resistance Level
- WF $54.72
- RPRX $38.00
- Average True Range (ATR)
- WF 1.01
- RPRX 0.68
- MACD
- WF -0.31
- RPRX -0.02
- Stochastic Oscillator
- WF 66.93
- RPRX 64.97
About WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. The operating segments of the company include Banking, Credit card, Capital, Investment banking, and others.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.